These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 23040796)

  • 1. Severely impaired health status at diagnosis of Pompe disease: a cross-sectional analysis to explore the potential utility of neonatal screening.
    Rigter T; Weinreich SS; van El CG; de Vries JM; van Gelder CM; Güngör D; Reuser AJ; Hagemans ML; Cornel MC; van der Ploeg AT
    Mol Genet Metab; 2012 Nov; 107(3):448-55. PubMed ID: 23040796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical sequelae of 17 cases with glycogen storage disease type II/Pompe disease].
    Zhang HB; Zhang WM; Qiu JJ; Meng Y; Qiu ZQ
    Zhonghua Er Ke Za Zhi; 2012 Jun; 50(6):415-9. PubMed ID: 22931935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pompe disease in infants: improving the prognosis by newborn screening and early treatment.
    Chien YH; Lee NC; Thurberg BL; Chiang SC; Zhang XK; Keutzer J; Huang AC; Wu MH; Huang PH; Tsai FJ; Chen YT; Hwu WL
    Pediatrics; 2009 Dec; 124(6):e1116-25. PubMed ID: 19948615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Newborn screening for Pompe disease: an update, 2011.
    Burton BK
    Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):8-12. PubMed ID: 22253219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early detection of Pompe disease by newborn screening is feasible: results from the Taiwan screening program.
    Chien YH; Chiang SC; Zhang XK; Keutzer J; Lee NC; Huang AC; Chen CA; Wu MH; Huang PH; Tsai FJ; Chen YT; Hwu WL
    Pediatrics; 2008 Jul; 122(1):e39-45. PubMed ID: 18519449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Newborn screening for Pompe disease in Japan.
    Oda E; Tanaka T; Migita O; Kosuga M; Fukushi M; Okumiya T; Osawa M; Okuyama T
    Mol Genet Metab; 2011 Dec; 104(4):560-5. PubMed ID: 21963784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cognitive and adaptive functioning of children with infantile Pompe disease treated with enzyme replacement therapy: long-term follow-up.
    Spiridigliozzi GA; Heller JH; Kishnani PS
    Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):22-9. PubMed ID: 22253038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Childhood Pompe disease: clinical spectrum and genotype in 31 patients.
    van Capelle CI; van der Meijden JC; van den Hout JM; Jaeken J; Baethmann M; Voit T; Kroos MA; Derks TG; Rubio-Gozalbo ME; Willemsen MA; Lachmann RH; Mengel E; Michelakakis H; de Jongste JC; Reuser AJ; van der Ploeg AT
    Orphanet J Rare Dis; 2016 May; 11(1):65. PubMed ID: 27189384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pompe disease, the must-not-miss diagnosis: A report of 3 patients.
    Dubrovsky A; Corderi J; Karasarides T; Taratuto AL
    Muscle Nerve; 2013 Apr; 47(4):594-600. PubMed ID: 23463700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disease severity in children and adults with Pompe disease related to age and disease duration.
    Hagemans ML; Winkel LP; Hop WC; Reuser AJ; Van Doorn PA; Van der Ploeg AT
    Neurology; 2005 Jun; 64(12):2139-41. PubMed ID: 15985590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Should we consider newborn screening for Pompe disease?].
    Lacombe D; Verloes A
    Arch Pediatr; 2014 Jun; 21(6):561-3. PubMed ID: 24768068
    [No Abstract]   [Full Text] [Related]  

  • 12. The prevalence and impact of scoliosis in Pompe disease: lessons learned from the Pompe Registry.
    Roberts M; Kishnani PS; van der Ploeg AT; Müller-Felber W; Merlini L; Prasad S; Case LE
    Mol Genet Metab; 2011 Dec; 104(4):574-82. PubMed ID: 21930409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening for Pompe disease in a Portuguese high risk population.
    Almeida V; Conceição I; Fineza I; Coelho T; Silveira F; Santos M; Valverde A; Geraldo A; Maré R; Aguiar TC; Mendonça C; Martins J; Medeiros L; Barroso C; Vieira JP; Moreno T; Negrão L; Dias MS; Lacerda L; Evangelista T
    Neuromuscul Disord; 2017 Aug; 27(8):777-781. PubMed ID: 28554557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term prognosis of patients with infantile-onset Pompe disease diagnosed by newborn screening and treated since birth.
    Chien YH; Lee NC; Chen CA; Tsai FJ; Tsai WH; Shieh JY; Huang HJ; Hsu WC; Tsai TH; Hwu WL
    J Pediatr; 2015 Apr; 166(4):985-91.e1-2. PubMed ID: 25466677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing disease severity in Pompe disease: the roles of a urinary glucose tetrasaccharide biomarker and imaging techniques.
    Young SP; Piraud M; Goldstein JL; Zhang H; Rehder C; Laforet P; Kishnani PS; Millington DS; Bashir MR; Bali DS
    Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):50-8. PubMed ID: 22252961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Open-label extension study following the Late-Onset Treatment Study (LOTS) of alglucosidase alfa.
    van der Ploeg AT; Barohn R; Carlson L; Charrow J; Clemens PR; Hopkin RJ; Kishnani PS; Laforêt P; Morgan C; Nations S; Pestronk A; Plotkin H; Rosenbloom BE; Sims KB; Tsao E
    Mol Genet Metab; 2012 Nov; 107(3):456-61. PubMed ID: 23031366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening for Pompe disease using a rapid dried blood spot method: experience of a clinical diagnostic laboratory.
    Goldstein JL; Young SP; Changela M; Dickerson GH; Zhang H; Dai J; Peterson D; Millington DS; Kishnani PS; Bali DS
    Muscle Nerve; 2009 Jul; 40(1):32-6. PubMed ID: 19533645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Late onset Pompe disease: clinical and neurophysiological spectrum of 38 patients including long-term follow-up in 18 patients.
    Müller-Felber W; Horvath R; Gempel K; Podskarbi T; Shin Y; Pongratz D; Walter MC; Baethmann M; Schlotter-Weigel B; Lochmüller H; Schoser B
    Neuromuscul Disord; 2007 Oct; 17(9-10):698-706. PubMed ID: 17643989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Practical Recommendations for Diagnosis and Management of Respiratory Muscle Weakness in Late-Onset Pompe Disease.
    Boentert M; Prigent H; Várdi K; Jones HN; Mellies U; Simonds AK; Wenninger S; Barrot Cortés E; Confalonieri M
    Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27763517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Facial-muscle weakness, speech disorders and dysphagia are common in patients with classic infantile Pompe disease treated with enzyme therapy.
    van Gelder CM; van Capelle CI; Ebbink BJ; Moor-van Nugteren I; van den Hout JM; Hakkesteegt MM; van Doorn PA; de Coo IF; Reuser AJ; de Gier HH; van der Ploeg AT
    J Inherit Metab Dis; 2012 May; 35(3):505-11. PubMed ID: 22008944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.